Combination chemotherapy with or without hexamethylmelamine in alkylating‐agent resistant ovarian carcinoma

J. P. Neijt, W. W Bokkel Ten Huinink, M. E L Der Van Burg, A. T. van Oosterom, C. D. Kooyman, J. C. van Houwelingen, H. M. Pinedo

Research output: Contribution to journalArticle

Abstract

The study was designed to determine the efficacy of a two‐drug and three‐drug combination chemotherapy regimen for patients with advanced epithelial ovarian carcinoma resistant to alkylating monotherapy. Patients were randomized to receive either Adriamycin (doxorubicin) and cis‐diamminedichloroplatinum(II) (AP) repeated every 3 weeks, or AP plus hexamethylmelamine (HAP) repeated every 5 weeks. Forty‐five patients were evaluable for response and 49 for survival. No significant differences were found between the treatment groups as to response rate, progression‐free survival, and survival. A remission was achieved in 20% of the patients and stable disease in another 20%. Median progression‐free survival of all patients was only 4 months (median survival, 6 months). All patients showed progressive disease within 13 months after the onset of chemotherapy. Patients responding to treatment and those with an interval of more than 2 years between the initial diagnosis and cancer recurrence, experienced prolonged survival. Two conclusions can be drawn from the results of this study; neither of the regimens is superior to the other, and the effect of both in alkylator‐resistant patients with ovarian cancer are meager. In studies on salvage chemotherapy, to the contrary, these combinations induced remissions in more than 40% of the patients. This difference in response rate might be due to differences between the prognostic factors of the patient populations. Better results are to be expected when these drugs are used in initial drug programs for previously untreated patients.

Original languageEnglish (US)
Pages (from-to)1467-1472
Number of pages6
JournalCancer
Volume53
Issue number7
DOIs
StatePublished - 1984
Externally publishedYes

Fingerprint

Altretamine
Combination Drug Therapy
Carcinoma
Survival
Doxorubicin
Drug Therapy
Pharmaceutical Preparations
Ovarian Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Neijt, J. P., Ten Huinink, W. W. B., Van Burg, M. E. L. D., van Oosterom, A. T., Kooyman, C. D., van Houwelingen, J. C., & Pinedo, H. M. (1984). Combination chemotherapy with or without hexamethylmelamine in alkylating‐agent resistant ovarian carcinoma. Cancer, 53(7), 1467-1472. https://doi.org/10.1002/1097-0142(19840401)53:7<1467::AID-CNCR2820530707>3.0.CO;2-2

Combination chemotherapy with or without hexamethylmelamine in alkylating‐agent resistant ovarian carcinoma. / Neijt, J. P.; Ten Huinink, W. W Bokkel; Van Burg, M. E L Der; van Oosterom, A. T.; Kooyman, C. D.; van Houwelingen, J. C.; Pinedo, H. M.

In: Cancer, Vol. 53, No. 7, 1984, p. 1467-1472.

Research output: Contribution to journalArticle

Neijt, JP, Ten Huinink, WWB, Van Burg, MELD, van Oosterom, AT, Kooyman, CD, van Houwelingen, JC & Pinedo, HM 1984, 'Combination chemotherapy with or without hexamethylmelamine in alkylating‐agent resistant ovarian carcinoma', Cancer, vol. 53, no. 7, pp. 1467-1472. https://doi.org/10.1002/1097-0142(19840401)53:7<1467::AID-CNCR2820530707>3.0.CO;2-2
Neijt, J. P. ; Ten Huinink, W. W Bokkel ; Van Burg, M. E L Der ; van Oosterom, A. T. ; Kooyman, C. D. ; van Houwelingen, J. C. ; Pinedo, H. M. / Combination chemotherapy with or without hexamethylmelamine in alkylating‐agent resistant ovarian carcinoma. In: Cancer. 1984 ; Vol. 53, No. 7. pp. 1467-1472.
@article{5ecafc2f5fdc4797b7e4b2b68a7f1bc0,
title = "Combination chemotherapy with or without hexamethylmelamine in alkylating‐agent resistant ovarian carcinoma",
abstract = "The study was designed to determine the efficacy of a two‐drug and three‐drug combination chemotherapy regimen for patients with advanced epithelial ovarian carcinoma resistant to alkylating monotherapy. Patients were randomized to receive either Adriamycin (doxorubicin) and cis‐diamminedichloroplatinum(II) (AP) repeated every 3 weeks, or AP plus hexamethylmelamine (HAP) repeated every 5 weeks. Forty‐five patients were evaluable for response and 49 for survival. No significant differences were found between the treatment groups as to response rate, progression‐free survival, and survival. A remission was achieved in 20{\%} of the patients and stable disease in another 20{\%}. Median progression‐free survival of all patients was only 4 months (median survival, 6 months). All patients showed progressive disease within 13 months after the onset of chemotherapy. Patients responding to treatment and those with an interval of more than 2 years between the initial diagnosis and cancer recurrence, experienced prolonged survival. Two conclusions can be drawn from the results of this study; neither of the regimens is superior to the other, and the effect of both in alkylator‐resistant patients with ovarian cancer are meager. In studies on salvage chemotherapy, to the contrary, these combinations induced remissions in more than 40{\%} of the patients. This difference in response rate might be due to differences between the prognostic factors of the patient populations. Better results are to be expected when these drugs are used in initial drug programs for previously untreated patients.",
author = "Neijt, {J. P.} and {Ten Huinink}, {W. W Bokkel} and {Van Burg}, {M. E L Der} and {van Oosterom}, {A. T.} and Kooyman, {C. D.} and {van Houwelingen}, {J. C.} and Pinedo, {H. M.}",
year = "1984",
doi = "10.1002/1097-0142(19840401)53:7<1467::AID-CNCR2820530707>3.0.CO;2-2",
language = "English (US)",
volume = "53",
pages = "1467--1472",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Combination chemotherapy with or without hexamethylmelamine in alkylating‐agent resistant ovarian carcinoma

AU - Neijt, J. P.

AU - Ten Huinink, W. W Bokkel

AU - Van Burg, M. E L Der

AU - van Oosterom, A. T.

AU - Kooyman, C. D.

AU - van Houwelingen, J. C.

AU - Pinedo, H. M.

PY - 1984

Y1 - 1984

N2 - The study was designed to determine the efficacy of a two‐drug and three‐drug combination chemotherapy regimen for patients with advanced epithelial ovarian carcinoma resistant to alkylating monotherapy. Patients were randomized to receive either Adriamycin (doxorubicin) and cis‐diamminedichloroplatinum(II) (AP) repeated every 3 weeks, or AP plus hexamethylmelamine (HAP) repeated every 5 weeks. Forty‐five patients were evaluable for response and 49 for survival. No significant differences were found between the treatment groups as to response rate, progression‐free survival, and survival. A remission was achieved in 20% of the patients and stable disease in another 20%. Median progression‐free survival of all patients was only 4 months (median survival, 6 months). All patients showed progressive disease within 13 months after the onset of chemotherapy. Patients responding to treatment and those with an interval of more than 2 years between the initial diagnosis and cancer recurrence, experienced prolonged survival. Two conclusions can be drawn from the results of this study; neither of the regimens is superior to the other, and the effect of both in alkylator‐resistant patients with ovarian cancer are meager. In studies on salvage chemotherapy, to the contrary, these combinations induced remissions in more than 40% of the patients. This difference in response rate might be due to differences between the prognostic factors of the patient populations. Better results are to be expected when these drugs are used in initial drug programs for previously untreated patients.

AB - The study was designed to determine the efficacy of a two‐drug and three‐drug combination chemotherapy regimen for patients with advanced epithelial ovarian carcinoma resistant to alkylating monotherapy. Patients were randomized to receive either Adriamycin (doxorubicin) and cis‐diamminedichloroplatinum(II) (AP) repeated every 3 weeks, or AP plus hexamethylmelamine (HAP) repeated every 5 weeks. Forty‐five patients were evaluable for response and 49 for survival. No significant differences were found between the treatment groups as to response rate, progression‐free survival, and survival. A remission was achieved in 20% of the patients and stable disease in another 20%. Median progression‐free survival of all patients was only 4 months (median survival, 6 months). All patients showed progressive disease within 13 months after the onset of chemotherapy. Patients responding to treatment and those with an interval of more than 2 years between the initial diagnosis and cancer recurrence, experienced prolonged survival. Two conclusions can be drawn from the results of this study; neither of the regimens is superior to the other, and the effect of both in alkylator‐resistant patients with ovarian cancer are meager. In studies on salvage chemotherapy, to the contrary, these combinations induced remissions in more than 40% of the patients. This difference in response rate might be due to differences between the prognostic factors of the patient populations. Better results are to be expected when these drugs are used in initial drug programs for previously untreated patients.

UR - http://www.scopus.com/inward/record.url?scp=0021333451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021333451&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19840401)53:7<1467::AID-CNCR2820530707>3.0.CO;2-2

DO - 10.1002/1097-0142(19840401)53:7<1467::AID-CNCR2820530707>3.0.CO;2-2

M3 - Article

C2 - 6421472

AN - SCOPUS:0021333451

VL - 53

SP - 1467

EP - 1472

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -